Cybin Provides Progress Update On Its CYB004-E Phase 1 Trial
Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce that its CYB004-E Phase 1